A detailed history of Shell Asset Management CO transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 20,572 shares of NTLA stock, worth $250,566. This represents 0.02% of its overall portfolio holdings.

Number of Shares
20,572
Previous 20,521 0.25%
Holding current value
$250,566
Previous $459,000 7.84%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$19.72 - $27.36 $1,005 - $1,395
51 Added 0.25%
20,572 $423,000
Q1 2024

Jul 31, 2024

SELL
$23.82 - $32.8 $36,206 - $49,855
-1,520 Reduced 6.9%
20,521 $459,000
Q1 2024

May 14, 2024

SELL
$23.82 - $32.8 $18,103 - $24,927
-760 Reduced 3.33%
22,041 $606,000
Q4 2023

Feb 14, 2024

SELL
$23.16 - $32.34 $37,519 - $52,390
-1,620 Reduced 6.63%
22,801 $695,000
Q3 2023

Nov 08, 2023

SELL
$31.62 - $45.78 $1,739 - $2,517
-55 Reduced 0.22%
24,421 $772,000
Q2 2023

Jul 28, 2023

BUY
$34.58 - $46.03 $787,870 - $1.05 Million
22,784 Added 1346.57%
24,476 $998,000
Q1 2023

May 15, 2023

SELL
$33.3 - $44.82 $199 - $268
-6 Reduced 0.35%
1,692 $63,000
Q4 2022

Feb 07, 2023

SELL
$33.21 - $62.69 $11,424 - $21,565
-344 Reduced 16.85%
1,698 $59,000
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $28,793 - $38,287
-534 Reduced 20.73%
2,042 $114,000
Q2 2022

Aug 09, 2022

BUY
$38.49 - $76.21 $153 - $304
4 Added 0.16%
2,576 $133,000
Q1 2022

May 04, 2022

SELL
$58.27 - $118.99 $22,142 - $45,216
-380 Reduced 12.87%
2,572 $187,000
Q4 2021

Feb 09, 2022

BUY
$100.76 - $138.36 $1,712 - $2,352
17 Added 0.58%
2,952 $349,000
Q3 2021

Nov 04, 2021

BUY
$132.37 - $176.78 $388,505 - $518,849
2,935 New
2,935 $394,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.